1. Stewart S., Hart C.L., Hole D.J., McMurray J.. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study.
Heart 86:2001;516–521.
2. Go A.S., Hylek E.M., Phillips K.A., Chang Y., Henault L.E., Selby J.V., Singer D.E.. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.
JAMA 285:2001;2370–2375.
3. Bansal N., Xie D., Tao K., Chen J., Deo R., Horwitz E., Hsu C.Y., Kallem R.K., Keane M.G., Lora C.M., Raj D., Soliman E.Z., Strauss L., Wolf M., Go A.S.; CRIC Study. Atrial fibrillation and risk of ESRD in adults with CKD.
Clin J Am Soc Nephrol 11:2016;1189–1196.
4. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery , Camm A.J., Kirchhof P., Lip G.Y., Schotten U., Savelieva I., Ernst S., Van Gelder I.C., Al-Attar N., Hindricks G., Prendergast B., Heidbuchel H., Alfieri O., Angelini A., Atar D., Colonna P., De Caterina R., De Sutter J., Goette A., Gorenek B., Heldal M., Hohloser S.H., Kolh P., Le Heuzey J.Y., Ponikowski P., Rutten F.H.. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).
Eur Heart J 31:2010;2369–2429.
5. Pokushalov E., Romanov A., Corbucci G., Artyomenko S., Baranova V., Turov A., Shirokova N., Karaskov A., Mittal S., Steinberg J.S.. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension.
J Am Coll Cardiol 60:2012;1163–1170.
6. Kiuchi M.G., Chen S., Andrea B.R., Kiuchi T., Carreira M.A., Graciano M.L., Lugon J.R.. Renal sympathetic denervation in patients with hypertension and chronic kidney disease: does improvement in renal function follow blood pressure control?
J Clin Hypertens (Greenwich) 16:2014;794–800.
7. Kiuchi M.G., Graciano M.L., Carreira M.A., Kiuchi T., Chen S., Lugon J.R.. Long-term effects of renal sympathetic denervation on hypertensive patients with mild to moderate chronic kidney disease.
J Clin Hypertens (Greenwich) 18:2016;190–196.
8. Kiuchi M.G., Mion D. Jr., Graciano M.L., de Queiroz Carreira M.A., Kiuchi T., Chen S., Lugon J.R.. Proof of concept study: improvement of echocardiographic parameters after renal sympathetic denervation in CKD refractory hypertensive patients.
Int J Cardiol 207:2016;6–12.
9. Schlaich M.P., Bart B., Hering D., Walton A., Marusic P., Mahfoud F., Böhm M., Lambert E.A., Krum H., Sobotka P.A., Schmieder R.E., Ika-Sari C., Eikelis N., Straznicky N., Lambert G.W., Esler M.D.. Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with the end-stage renal disease.
Int J Cardiol 168:2013;2214–2220.
10. Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A., Böhm M., Christiaens T., Cifkova R., De Backer G., Dominiczak A., Galderisi M., Grobbee D.E., Jaarsma T., Kirchhof P., Kjeldsen S.E., Laurent S., Manolis A.J., Nilsson P.M., Ruilope L.M., Schmieder R.E., Sirnes P.A., Sleight P., Viigimaa M., Waeber B., Zannad F., Redon J., Dominiczak A., Narkiewicz K., Nilsson P.M., Burnier M., Viigimaa M., Ambrosioni E., Caufield M., Coca A., Olsen M.H., Schmieder R.E., Tsioufis C., van de Borne P., Zamorano J.L., Achenbach S., Baumgartner H., Bax J.J., Bueno H., Dean V., Deaton C., Erol C., Fagard R., Ferrari R., Hasdai D., Hoes A.W., Kirchhof P., Knuuti J., Kolh P., Lancellotti P., Linhart A., Nihoyannopoulos P., Piepoli M.F., Ponikowski P., Sirnes P.A., Tamargo J.L., Tendera M., Torbicki A., Wijns W., Windecker S., Clement D.L., Coca A., Gillebert T.C., Tendera M., Rosei E.A., Ambrosioni E., Anker S.D., Bauersachs J., Hitij J.B., Caulfield M., De Buyzere M., De Geest S., Derumeaux G.A., Erdine S., Farsang C., Funck-Brentano C., Gerc V., Germano G., Gielen S., Haller H., Hoes A.W., Jordan J., Kahan T., Komajda M., Lovic D., Mahrholdt H., Olsen M.H., Ostergren J., Parati G., Perk J., Polonia J., Popescu B.A., Reiner Z., Rydén L., Sirenko Y., Stanton A., Struijker-Boudier H., Tsioufis C., van de Borne P., Vlachopoulos C., Volpe M., Wood D.A.. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
Eur Heart J 34:2013;2159–2219.
11. Levey A.S., Stevens L.A., Schmid C.H., Zhang Y.L., Castro A.F. 3rd, Feldman H.I., Kusek J.W., Eggers P., Van Lente F., Greene T., Coresh J.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate.
Ann Intern Med 150:2009;604–612.
12. Joshi S., Choi A.D., Kamath G.S., Raiszadeh F., Marrero D., Badheka A., Mittal S., Steinberg J.S.. Prevalence, predictors, and prognosis of atrial fibrillation early after pulmonary vein isolation: findings from 3 months of continuous automatic ECG loop recordings.
J Cardiovasc Electrophysiol 20:2009;1089–1094.
13. Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A., Foster E., Pellikka P.A., Picard M.H., Roman M.J., Seward J., Shanewise J.S., Solomon S.D., Spencer K.T., Sutton M.S., Stewart W.J.; Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.
J Am Soc Echocardiogr 18:2005;1440–1463.
14. Devereux R.B., Alonso D.R., Lutas E.M., Gottlieb G.J., Campo E., Sachs I., Reichek N.. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings.
Am J Cardiol 57:1986;450–458.
15. Mosteller R.D.. Simplified calculation of body-surface area.
N Engl J Med 317:1987 1098.[Correspondence].
16. Stergiou G.S., Kollias A., Destounis A., Tzamouranis D.. Automated blood pressure measurement in atrial fibrillation: a systematic review and meta-analysis. J Hypertens 30:2012;2074–2082.
17. Pokushalov E., Romanov A., Corbucci G., Artyomenko S., Turov A., Shirokova N., Karaskov A.. Ablation of paroxysmal and persistent atrial fibrillation: 1-year follow-up through continuous subcutaneous monitoring.
J Cardiovasc Electrophysiol 22:2011;369–375.
18. Merten G.J., Burgess W.P., Rittase R.A., Kennedy T.P.. Prevention of contrast-induced nephropathy with sodium bicarbonate: an evidence-based protocol.
Crit Pathw Cardiol 3:2004;138–143.
19. ten Dam M.A., Wetzels J.F.. Toxicity of contrast media: an update.
Neth J Med 66:2008;416–422.
20. Azizi M., Sapoval M., Gosse P., Monge M., Bobrie G., Delsart P., Midulla M., Mounier-Véhier C., Courand P.Y., Lantelme P., Denolle T., Dourmap-Collas C., Trillaud H., Pereira H., Plouin P.F., Chatellier G.; Renal Denervation for Hypertension (DENERHTN) investigators. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial.
Lancet 385:2015;1957–1965.
21. De Jager R.L., Sanders M.F., Bots M.L., Lobo M.D., Ewen S., Beeftink M.M., Böhm M., Daemen J., Dörr O., Hering D., Mahfoud F., Nef H., Ott C., Saxena M., Schmieder R.E., Schlaich M.P., Spiering W., Tonino P.A., Verloop W.L., Vink E.E., Vonken E.J., Voskuil M., Worthley S.G., Blankestijn P.J.. Renal denervation in hypertensive patients not on blood pressure lowering drugs.
Clin Res Cardiol 105:2016;755–762.
22. Bakris G.L., Townsend R.R., Flack J.M., Brar S., Cohen S.A., D'Agostino R., Kandzari D.E., Katzen B.T., Leon M.B., Mauri L., Negoita M., O'Neill W.W., Oparil S., Rocha-Singh K., Bhatt D.L.; SYMPLICITY HTN-3 Investigators. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial.
J Am Coll Cardiol 65:2015;1314–1321.
23. Kandzari D.E., Bhatt D.L., Brar S., Devireddy C.M., Esler M., Fahy M., Flack J.M., Katzen B.T., Lea J., Lee D.P., Leon M.B., Ma A., Massaro J., Mauri L., Oparil S., O'Neill W.W., Patel M.R., Rocha-Singh K., Sobotka P.A., Svetkey L., Townsend R.R., Bakris G.L.. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial.
Eur Heart J 36:2015;219–227.
24. Kiuchi M.G., Maia G.L., de Queiroz Carreira M.A., Kiuchi T., Chen S., Andrea B.R., Graciano M.L., Lugon J.R.. Effects of renal denervation with a standard irrigated cardiac ablation catheter on blood pressure and renal function in patients with chronic kidney disease and resistant hypertension.
Eur Heart J 34:2013;2114–2121.
25. Krum H., Schlaich M., Whitbourn R., Sobotka P.A., Sadowski J., Bartus K., Kapelak B., Walton A., Sievert H., Thambar S., Abraham W.T., Esler M.. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.
Lancet 373:2009;1275–1281.
26. Symplicity HTN-1 Investigators . Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months.
Hypertension 57:2011;911–917.
27. Grassi G.. Sympathetic neural activity in hypertension and related diseases.
Am J Hypertens 23:2010;1052–1060.
28. Grassi G.. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives.
Hypertension 54:2009;690–697.
29. Paton J.F., Raizada M.K.. Neurogenic hypertension.
Exp Physiol 95:2010;569–571.
30. Schlaich M.P., Socratous F., Hennebry S., Eikelis N., Lambert E.A., Straznicky N., Esler M.D., Lambert G.W.. Sympathetic activation in chronic renal failure.
J Am Soc Nephrol 20:2009;933–939.
31. Neumann J., Ligtenberg G., Klein I.I., Koomans H.A., Blankestijn P.J.. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment.
Kidney Int 65:2004;1568–1576.
32. McGrath B.P., Ledingham J.G., Benedict C.R.. Catecholamines in peripheral venous plasma in patients on chronic haemodialysis.
Clin Sci Mol Med 55:1978;89–96.
33. Grassi G., Bertolli S., Seravalle G.. Sympathetic nervous system: role in hypertension and in chronic kidney disease.
Curr Opin Nephrol Hypertens 21:2012;46–51.
34. Zoccali C., Mallamaci F., Parlongo S., Cutrupi S., Benedetto F.A., Tripepi G., Bonanno G., Rapisarda F., Fatuzzo P., Seminara G., Cataliotti A., Stancanelli B., Malatino L.S.. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease.
Circulation 105:2002;1354–1359.
35. Wang L., Lu C.Z., Zhang X., Luo D., Zhao B., Yu X., Xia D.S., Chen X., Zhao X.D.. The effect of catheter based renal sympathetic denervation on renin-angiotensin-aldosterone system in patients with resistant hypertension.
Zhonghua Xin Xue Guan Bing Za Zhi 41:2013;3–7.
36. Brandt M.C., Mahfoud F., Reda S., Schirmer S.H., Erdmann E., Böhm M., Hoppe U.C.. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension.
J Am Coll Cardiol 59:2012;901–909.